(1)
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, Meiji ) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, Dong-A ).
DMB-3115 is a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of patients with several inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn s disease and ulcerative colitis. Meiji and Dong-A are co-developing DMB-3115 under the strategic collaboration partnership agreement on biosimilars signed in September 2011. DMB-3115 is produce
(0)
First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, Dong-A ). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, Dong-A ).).
The updated release reads:
MEIJI SEIKA PHARMA:
PROMISING RESULTS OF PHASE I CLINICAL TRIAL OF DMB-3115, A PROPOSED USTEKINUMAB BIOSIMILAR, AND INITIATION OF PHASE III CLINICAL TRIAL IN PATIENTS WITH PLAQUE PSORIASIS
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, Meiji ) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regio
Redirecting to UPL Announces Collaboration With Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
To develop and commercialize fomulations of Flupyrimin for rice in Southeast AsiaUPL announced that its subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma Co., Ltd. for exclusive access to Flupyrimin for rice in Southeast Asia.
Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going
collaboration between the two companies with this compound.
In addition to this latest arrangement, in 2018 UPL s subsidiary and Meiji entered into an exclusive licensing agreement for UPL to commercialize formulations of Flupyrimin for applications in rice in India. Furthermore, in 2020, the two companies signed a long-term global commercial exclusive agreement, excluding Japan, South Korea and Taiwan and non-exclusive in China, to use Flupyrimin in seed treatment
UPL Announces Collaboration With Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.